Get the Stockscreener App
53.24
15.84%
7.28
After Hours:
53.24
Sol Gel Technologies Ltd stock is traded at $53.24, with a volume of 20,705.
It is up +15.84% in the last 24 hours and up +31.46% over the past month.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
See More
Previous Close:
$45.96
Open:
$46.23
24h Volume:
20,705
Relative Volume:
1.10
Market Cap:
$148.32M
Revenue:
$23.93M
Net Income/Loss:
$-3.41M
P/E Ratio:
-46.70
EPS:
-1.14
Net Cash Flow:
$-33.87M
1W Performance:
+26.34%
1M Performance:
+31.46%
6M Performance:
+630.32%
1Y Performance:
+280.29%
1-Day Range:
$46.00
$54.54
1-Week Range:
$41.68
$54.54
52-Week Range:
$4.018
$54.54
Sol Gel Technologies Ltd Stock (SLGL) Company Profile
Name
Sol Gel Technologies Ltd
Sector
Industry
Phone
-
Address
-
Compare SLGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLGL
Sol Gel Technologies Ltd
|
53.24 | 128.03M | 23.93M | -3.41M | -33.87M | -1.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sol Gel Technologies Ltd Stock (SLGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Dec-31-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-19 | Reiterated | JMP Securities | Mkt Outperform |
Sol Gel Technologies Ltd Stock (SLGL) Latest News
Opaleye Management Inc. Increases Stake in Sol-Gel Technologies Ltd - GuruFocus
Rosacea Market Research and Forecast Report 2025-2035: Galderma, AbbVie, Bausch Health, Journey Medical, and Sol-Gel Drive Innovation Through Expanded R&D and Clinical TrialsResearchAndMarkets.com - The AI Journal
Opaleye Management Inc. Buys 22,497 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock - Defense World
Opaleye Management Inc. Acquires 35,169 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock - Defense World
Weekly Analysts’ Ratings Changes for Sol-Gel Technologies (SLGL) - Defense World
Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $361,500.30 in Stock - MarketBeat
Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Purchases 35,169 Shares of Stock - MarketBeat
Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $10,831.60 in Stock - MarketBeat
Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Buys 1,019 Shares of Stock - MarketBeat
Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $67,771.68 in Stock - MarketBeat
We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Easily Afford To Drive Business Growth - Yahoo Finance
Sol-Gel Technologies (SLGL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
What is HC Wainwright's Estimate for SLGL FY2025 Earnings? - MarketBeat
What analysts say about Sol Gel Technologies Ltd stockAI-Driven Market Analysis & Small Investment Capital Gains - earlytimes.in
Sol-Gel Technologies’ (SLGL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Sol-Gel Technologies (NASDAQ:SLGL) Receives "Buy" Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Sol-Gel Technologies (SLGL) Buy Recommendation - Nasdaq
SLGL: HC Wainwright & Co. Reiterates Buy Rating with $50 Price T - GuruFocus
What dividend safety score for Sol Gel Technologies Ltd. stockWeekly Market Summary & Free Community Supported Trade Ideas - Улправда
Will Sol Gel Technologies Ltd. stock gain from lower inflationJuly 2025 WrapUp & Community Shared Stock Ideas - Улправда
How rising interest rates impact Sol Gel Technologies Ltd. stock2025 Support & Resistance & Weekly Top Stock Performers List - Улправда
Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 2,735 Shares of Stock - MarketBeat
Owner Opaleye Management Inc Buys 2,735 ($110.4K) Of Sol-Gel Technologies Ltd [SLGL] - TradingView — Track All Markets
How analysts rate Sol Gel Technologies Ltd. stock todayJuly 2025 Chart Watch & Fast Entry High Yield Tips - bolumsonucanavari.com
Is Sol Gel Technologies Ltd. stock a buy before product launchesQuarterly Profit Report & Daily Technical Forecast Reports - DonanımHaber
Why Sol Gel Technologies Ltd. stock could see breakout soonMarket Trend Review & Consistent Profit Alerts - DonanımHaber
Will Sol Gel Technologies Ltd. stock benefit from upcoming earnings reports2025 Valuation Update & Safe Capital Growth Plans - Улправда
Sol-Gel Technologies (SLGL) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Sol-Gel to End SGT-210 Trial in Darier Disease - marketscreener.com
Sol-Gel halts Darier disease treatment after failed clinical trial By Investing.com - Investing.com Nigeria
Why Is Small Cap Sol-Gel Tech Stock Falling Today? - Benzinga
Sol-Gel Technologies Updates Clinical Pipeline Following Phase 1b Results - TipRanks
Sol-Gel Technologies (SLGL) files update on SGT-210 Darier Phase 1b - Stock Titan
Sol-Gel halts studies for rare disease drug (SLGL:NASDAQ) - Seeking Alpha
Sol-Gel Technologies (SLGL) Discontinues SGT-210 Development for Darier Disease - GuruFocus
Sol-Gel halts Darier disease treatment after failed clinical trial - Investing.com
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease - The Manila Times
Rare skin disease trial shows no clear gain, research focus shifts - Stock Titan
Owner Opaleye Management Inc Buys 87 ($3.5K) Of Sol-Gel Technologies Ltd [SLGL] - TradingView — Track All Markets
Sol-Gel Technologies (SLGL) insider files report on new share purchase - Stock Titan
Exit Recap: Will Sol Gel Technologies Ltd stock recover faster than peersQuarterly Market Review & Weekly Setup with ROI Potential - moha.gov.vn
Revenues Not Telling The Story For Sol-Gel Technologies Ltd. (NASDAQ:SLGL) After Shares Rise 30% - Sahm
Owner Opaleye Management Inc Buys 744 ($29.5K) Of Sol-Gel Technologies Ltd [SLGL] - TradingView — Track All Markets
What drives Sol Gel Technologies Ltd stock priceRisk Management Strategies & Big Profit Low Trading - earlytimes.in
What dividend safety score for Sol Gel Technologies Ltd stockShort Setup & Consistent Profit Trading Strategies - moha.gov.vn
Is Sol Gel Technologies Ltd. (4SG) stock trading at attractive multiples2025 Price Targets & Real-Time Price Movement Reports - Newser
How higher bond yields impact Sol Gel Technologies Ltd. (4SG) stockPortfolio Update Report & Free Risk Controlled Daily Trade Plans - Newser
Opaleye Management Inc. Buys 2,524 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock - MarketBeat
Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $162,185.80 in Stock - MarketBeat
How Sol Gel Technologies Ltd. stock benefits from strong dollarJuly 2025 Decliners & Fast Entry Momentum Alerts - Newser
Will Sol Gel Technologies Ltd. (4SG) stock benefit from commodity supercycleWeekly Market Outlook & Target Return Focused Stock Picks - Newser
Sol Gel Technologies Ltd Stock (SLGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):